Survey of current practices from the International Stereotactic Body Radiotherapy Consortium (ISBRTC) for head and neck cancers

Irene Karam; Min Yao; Dwight E. Heron; Ian Poon; Shlomo A. Koyfman; Sue S. Yom; Farzan Siddiqui; Eric Lartigau; Mustafa Cengiz; Hideya Yamazaki; Wendy Hara; Jack Phan; John A. Vargo; Victor Lee; Robert L. Foote; K. William Harter; Nancy Y. Lee; Arjun Sahgal; Simon S. Lo

doi:10.2217/fon-2016-0403

Survey of current practices from the International Stereotactic Body Radiotherapy Consortium (ISBRTC) for head and neck cancers

Irene Karam, Min Yao, Dwight E. Heron, Ian Poon, Shlomo A. Koyfman, Sue S. Yom, Farzan Siddiqui, Eric Lartigau, Mustafa Cengiz, Hideya Yamazaki, Wendy Hara, Jack Phan, John A. Vargo, Victor Lee, Robert L. Foote, K. William Harter, Nancy Y. Lee, Arjun Sahgal, Simon S. Lo

Radiation Oncology

Research output: Contribution to journal › Article › peer-review

33 Scopus citations

Abstract

Aim: To provide a multi-institutional description of current practices of stereotactic body radiotherapy (SBRT) for head and neck cancer. Materials & methods: 15 international institutions with significant experience in head and neck SBRT were asked to complete a questionnaire covering clinical and technical factors. Results: SBRT is used 10-100% of the time for recurrent primary head and neck cancer, and 0-10% of the time in newly diagnosed disease. Five centers use a constraint for primary disease of 3-5 cm and 25-30 cc. Nine institutions apply a clinical target volume expansion of 1-10 mm and 14 use a planning target volume margin of 1-5 mm. Fractionation regimens vary between 15 and 22 Gy in 1 fraction to 30-50 Gy in 5 or 6 fractions. The risk of carotid blowout quoted in the re-irradiation setting ranges from 3 to 20%. Conclusion: There is considerable heterogeneity in patient selection and techniques in head and neck SBRT practice among experienced centers.

Original language	English (US)
Pages (from-to)	603-613
Number of pages	11
Journal	Future Oncology
Volume	13
Issue number	7
DOIs	https://doi.org/10.2217/fon-2016-0403
State	Published - Mar 2017

Keywords

SBRT
ablation
head and neck cancer
patterns of practice
stereotactic

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.2217/fon-2016-0403

Cite this

Karam, I., Yao, M., Heron, D. E., Poon, I., Koyfman, S. A., Yom, S. S., Siddiqui, F., Lartigau, E., Cengiz, M., Yamazaki, H., Hara, W., Phan, J., Vargo, J. A., Lee, V., Foote, R. L., Harter, K. W., Lee, N. Y., Sahgal, A., & Lo, S. S. (2017). Survey of current practices from the International Stereotactic Body Radiotherapy Consortium (ISBRTC) for head and neck cancers. Future Oncology, 13(7), 603-613. https://doi.org/10.2217/fon-2016-0403

Karam, I, Yao, M, Heron, DE, Poon, I, Koyfman, SA, Yom, SS, Siddiqui, F, Lartigau, E, Cengiz, M, Yamazaki, H, Hara, W, Phan, J, Vargo, JA, Lee, V, Foote, RL, Harter, KW, Lee, NY, Sahgal, A & Lo, SS 2017, 'Survey of current practices from the International Stereotactic Body Radiotherapy Consortium (ISBRTC) for head and neck cancers', Future Oncology, vol. 13, no. 7, pp. 603-613. https://doi.org/10.2217/fon-2016-0403

@article{570c8f49c70d49cbb76d49734d245601,

title = "Survey of current practices from the International Stereotactic Body Radiotherapy Consortium (ISBRTC) for head and neck cancers",

abstract = "Aim: To provide a multi-institutional description of current practices of stereotactic body radiotherapy (SBRT) for head and neck cancer. Materials & methods: 15 international institutions with significant experience in head and neck SBRT were asked to complete a questionnaire covering clinical and technical factors. Results: SBRT is used 10-100% of the time for recurrent primary head and neck cancer, and 0-10% of the time in newly diagnosed disease. Five centers use a constraint for primary disease of 3-5 cm and 25-30 cc. Nine institutions apply a clinical target volume expansion of 1-10 mm and 14 use a planning target volume margin of 1-5 mm. Fractionation regimens vary between 15 and 22 Gy in 1 fraction to 30-50 Gy in 5 or 6 fractions. The risk of carotid blowout quoted in the re-irradiation setting ranges from 3 to 20%. Conclusion: There is considerable heterogeneity in patient selection and techniques in head and neck SBRT practice among experienced centers.",

keywords = "SBRT, ablation, head and neck cancer, patterns of practice, stereotactic",

author = "Irene Karam and Min Yao and Heron, {Dwight E.} and Ian Poon and Koyfman, {Shlomo A.} and Yom, {Sue S.} and Farzan Siddiqui and Eric Lartigau and Mustafa Cengiz and Hideya Yamazaki and Wendy Hara and Jack Phan and Vargo, {John A.} and Victor Lee and Foote, {Robert L.} and Harter, {K. William} and Lee, {Nancy Y.} and Arjun Sahgal and Lo, {Simon S.}",

note = "Publisher Copyright: {\textcopyright} 2016 Future Medicine Ltd.",

year = "2017",

month = mar,

doi = "10.2217/fon-2016-0403",

language = "English (US)",

volume = "13",

pages = "603--613",

journal = "Future Oncology",

issn = "1479-6694",

publisher = "Future Medicine Ltd.",

number = "7",

}

TY - JOUR

T1 - Survey of current practices from the International Stereotactic Body Radiotherapy Consortium (ISBRTC) for head and neck cancers

AU - Karam, Irene

AU - Yao, Min

AU - Heron, Dwight E.

AU - Poon, Ian

AU - Koyfman, Shlomo A.

AU - Yom, Sue S.

AU - Siddiqui, Farzan

AU - Lartigau, Eric

AU - Cengiz, Mustafa

AU - Yamazaki, Hideya

AU - Hara, Wendy

AU - Phan, Jack

AU - Vargo, John A.

AU - Lee, Victor

AU - Foote, Robert L.

AU - Harter, K. William

AU - Lee, Nancy Y.

AU - Sahgal, Arjun

AU - Lo, Simon S.

PY - 2017/3

Y1 - 2017/3

N2 - Aim: To provide a multi-institutional description of current practices of stereotactic body radiotherapy (SBRT) for head and neck cancer. Materials & methods: 15 international institutions with significant experience in head and neck SBRT were asked to complete a questionnaire covering clinical and technical factors. Results: SBRT is used 10-100% of the time for recurrent primary head and neck cancer, and 0-10% of the time in newly diagnosed disease. Five centers use a constraint for primary disease of 3-5 cm and 25-30 cc. Nine institutions apply a clinical target volume expansion of 1-10 mm and 14 use a planning target volume margin of 1-5 mm. Fractionation regimens vary between 15 and 22 Gy in 1 fraction to 30-50 Gy in 5 or 6 fractions. The risk of carotid blowout quoted in the re-irradiation setting ranges from 3 to 20%. Conclusion: There is considerable heterogeneity in patient selection and techniques in head and neck SBRT practice among experienced centers.

AB - Aim: To provide a multi-institutional description of current practices of stereotactic body radiotherapy (SBRT) for head and neck cancer. Materials & methods: 15 international institutions with significant experience in head and neck SBRT were asked to complete a questionnaire covering clinical and technical factors. Results: SBRT is used 10-100% of the time for recurrent primary head and neck cancer, and 0-10% of the time in newly diagnosed disease. Five centers use a constraint for primary disease of 3-5 cm and 25-30 cc. Nine institutions apply a clinical target volume expansion of 1-10 mm and 14 use a planning target volume margin of 1-5 mm. Fractionation regimens vary between 15 and 22 Gy in 1 fraction to 30-50 Gy in 5 or 6 fractions. The risk of carotid blowout quoted in the re-irradiation setting ranges from 3 to 20%. Conclusion: There is considerable heterogeneity in patient selection and techniques in head and neck SBRT practice among experienced centers.

KW - SBRT

KW - ablation

KW - head and neck cancer

KW - patterns of practice

KW - stereotactic

UR - http://www.scopus.com/inward/record.url?scp=85012094004&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85012094004&partnerID=8YFLogxK

U2 - 10.2217/fon-2016-0403

DO - 10.2217/fon-2016-0403

M3 - Article

C2 - 27842456

AN - SCOPUS:85012094004

SN - 1479-6694

VL - 13

SP - 603

EP - 613

JO - Future Oncology

JF - Future Oncology

IS - 7

ER -

Survey of current practices from the International Stereotactic Body Radiotherapy Consortium (ISBRTC) for head and neck cancers

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this